drugset / Trial / NCT03906006
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of ABP-671 administered orally in healthy volunteers.
Timeline
- Start
- 2018-10-17
- Primary completion
- 2019-06-20
- Completion
- 2019-06-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABP-671 | Unknown | 0.1 mg | Oral |
| Subject | ABP-671 | Unknown | 0.5 mg | Oral |
| Subject | ABP-671 | Unknown | 1 mg | Oral |
| Subject | ABP-671 | Unknown | 50 mg | Oral |